Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with
recurrent or advanced endometrial cancer. Akt inhibitor MK2206 may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.